BR112012022338A2 - anticorpos monoclonais direcionados a cd20 - Google Patents

anticorpos monoclonais direcionados a cd20

Info

Publication number
BR112012022338A2
BR112012022338A2 BR112012022338A BR112012022338A BR112012022338A2 BR 112012022338 A2 BR112012022338 A2 BR 112012022338A2 BR 112012022338 A BR112012022338 A BR 112012022338A BR 112012022338 A BR112012022338 A BR 112012022338A BR 112012022338 A2 BR112012022338 A2 BR 112012022338A2
Authority
BR
Brazil
Prior art keywords
monoclonal antibodies
canine
targeted
targeted monoclonal
antibodies
Prior art date
Application number
BR112012022338A
Other languages
English (en)
Inventor
Hansen Genevieve
Original Assignee
Vet Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vet Therapeutics Inc filed Critical Vet Therapeutics Inc
Publication of BR112012022338A2 publication Critical patent/BR112012022338A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

anticorpos monoclonais direcionados a cd20. a invenção proporciona anticorpo a antígenos canino ou felino. especificamente, anticorpos direcionados a cd20 caninos que foram caninizados ou felinizados são fornecidos. também são fornecidos métodos de preparação de anticorpos de elevada afinidade a cd20 canino e felino bem como métodos para tratar distúrbios de células-b em animais de companhia.
BR112012022338A 2010-03-04 2011-03-04 anticorpos monoclonais direcionados a cd20 BR112012022338A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31044010P 2010-03-04 2010-03-04
PCT/US2011/000415 WO2011109108A1 (en) 2010-03-04 2011-03-04 Monoclonal antibodies directed to cd20

Publications (1)

Publication Number Publication Date
BR112012022338A2 true BR112012022338A2 (pt) 2017-02-14

Family

ID=44542488

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012022338A BR112012022338A2 (pt) 2010-03-04 2011-03-04 anticorpos monoclonais direcionados a cd20

Country Status (6)

Country Link
EP (1) EP2542262A4 (pt)
JP (2) JP5911813B2 (pt)
AU (2) AU2011221553B2 (pt)
BR (1) BR112012022338A2 (pt)
CA (1) CA2791560A1 (pt)
WO (1) WO2011109108A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569460B2 (en) 2009-03-25 2013-10-29 Vet Therapeutics, Inc. Antibody constant domain regions and uses thereof
US8652470B2 (en) 2010-03-04 2014-02-18 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD52
SG194795A1 (en) * 2011-05-06 2013-12-30 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
AU2012328819B2 (en) * 2011-10-26 2017-08-03 Elanco Tiergesundheit Ag Monoclonal antibodies and methods of use
DK3416984T3 (da) * 2016-02-18 2021-04-26 Elanco Us Inc Kimært hunde-anti-cd20-antistof
JP2019026625A (ja) * 2017-08-03 2019-02-21 日本全薬工業株式会社 抗イヌｃｄ２０モノクローナル抗体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP3919830B2 (ja) * 1992-11-28 2007-05-30 財団法人化学及血清療法研究所 抗ネコヘルペスウイルス−１組換え抗体および該抗体をコードする遺伝子断片
JP3087696B2 (ja) 1997-07-25 2000-09-11 日本電気株式会社 分散メモリ型マルチプロセッサ・システム制御方法およびコンピュータ読み取り可能な記録媒体
DE60035369T2 (de) 1999-12-30 2008-02-28 Dana-Farber Cancer Institute, Inc., Boston Proteoliposomen, die ein integral membranprotein mit einer oder memhreren transmembrandomänen enthalten
CA2469833C (en) * 2001-12-21 2008-05-20 Idexx Laboratories, Inc. Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
CA2476166C (en) * 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
JP5354835B2 (ja) * 2002-11-07 2013-11-27 イミュノジェン・インコーポレーテッド 抗ｃｄ３３抗体、及びそれを用いた急性骨髄性白血病の治療方法
WO2006007202A2 (en) * 2004-05-28 2006-01-19 Idexx Laboratories, Inc Canine cd20 compositions
GB0707640D0 (en) 2007-04-20 2007-05-30 Strathclyde Acoustic deterrence
WO2010027488A2 (en) 2008-09-04 2010-03-11 Vet Therapeutics, Inc. Monoclonal antibodies

Also Published As

Publication number Publication date
AU2011221553B2 (en) 2016-05-26
EP2542262A4 (en) 2014-02-26
AU2011221553A1 (en) 2012-10-25
AU2016216710A1 (en) 2016-09-08
JP2013520990A (ja) 2013-06-10
CA2791560A1 (en) 2011-09-09
EP2542262A1 (en) 2013-01-09
WO2011109108A1 (en) 2011-09-09
JP5911813B2 (ja) 2016-04-27
JP2016179978A (ja) 2016-10-13

Similar Documents

Publication Publication Date Title
CY1122278T1 (el) Αντι il-36r αντισωματα
BR112012022342A2 (pt) anticorpos monoclonais dirigidos a cd52
EA201390933A1 (ru) Антитела против мезотелина и иммуноконъюгаты
TR201905458T4 (tr) Fap ve dr5 için spesifik bispesifik antikorlar, dr5 için spesifik antikorlar ve bunların kullanım yöntemleri.
EA201891641A1 (ru) Химерные антигенные рецепторы, нацеленные на вариант iii рецептора эпидермального фактора роста
EA201400875A1 (ru) Антитела к cd47 и способы их применения
UA116873C2 (uk) Антитіло, яке зв'язується з ox40
BR112016000666A2 (pt) Constructos de ligação de antígeno cd3 e cd19 biespecíficos
EA201300978A1 (ru) Антитела к сеа
BR112016014284A2 (pt) anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
MX2016003744A (es) Anticuerpos tem8 y su uso.
UA115439C2 (uk) Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
MA34091B1 (fr) Anticorps anti-cd40
BR112012022338A2 (pt) anticorpos monoclonais direcionados a cd20
EA201600252A1 (ru) Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования
BR112013028523A8 (pt) Uso de um anticorpo ou uma proteína de fusão ou um fragmento de ligação da mesma e método para a purificação de um anticorpo, uma proteína de fusão ou um fragmento de ligação da mesma de uma mistura fonte
EA201391342A1 (ru) Cd37-связывающие молекулы и их иммуноконъюгаты
EA201300819A1 (ru) Молекулы антител, которые связываются с il-17a и il-17f
ECSP13012673A (es) Métodos y composiciones para inmunoterapia para enfermedad neural
TN2014000513A1 (en) Dual receptor antagonistic antigen-binding proteins and uses thereof
EA201591191A1 (ru) Антитела против ntb-a и связанные с ними композиции и способы

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa)
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 8A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2504 DE 02/01/2019.